ALDX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALDX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Aldeyra Therapeutics's EBITDA for the three months ended in Dec. 2024 was $-15.27 Mil. Aldeyra Therapeutics's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Aldeyra Therapeutics's EBITDA margin for the quarter that ended in Dec. 2024 was 0.00%.
The historical data trend for Aldeyra Therapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aldeyra Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
EBITDA Margin % | Get a 7-Day Free Trial |
![]() |
![]() |
- | - | - | - | - |
Aldeyra Therapeutics Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
EBITDA Margin % | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
- | - | - | - | - |
For the Biotechnology subindustry, Aldeyra Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Aldeyra Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Aldeyra Therapeutics's EBITDA Margin % falls into.
EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.
Aldeyra Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as
Aldeyra Therapeutics's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aldeyra Therapeutics (NAS:ALDX) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Thank you for viewing the detailed overview of Aldeyra Therapeutics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Stephen Machatha | officer: Chief Development Officer | 131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421 |
Bruce Greenberg | officer: See Remarks | C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421 |
Perceptive Life Sciences Master Fund Ltd | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Todd C Brady | director, officer: President and CEO | C/O EVOKE PHARMA, INC., 505 LOMAS SANTA FE DRIVE, SOLANA BEACH CA 92075 |
Nancy Miller-rich | director | C/O INTERCEPT PHARMACEUTICALS, INC., 10 HUDSON YARDS, 37TH FL, NEW YORK NY 10001 |
Martin Joseph Joyce | director | 1050 HINGHAM STREET, ROCKLAND MA 02370 |
Joseph Edelman | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Perceptive Advisors Llc | 10 percent owner | 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Richard Douglas | director | ONE KENDALL SQUARE, CAMBRIDGE MA 02139 |
Ben Bronstein | director | 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803 |
David J Clark | officer: Chief Medical Officer | 131 HARTWELL AVE, LEXINGTON MA 02421 |
David Mcmullin | officer: SVP Corp. Dev. & Strategy | C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421 |
Joshua Reed | officer: Chief Financial Officer | C/O ALDEYRA THERAPEUTICS, INC., 131 HARTWELL AVENUE, SUITE 320, LEXINGTON MA 02421 |
Jesse I Treu | director, 10 percent owner | |
Stephen J Tulipano | officer: Chief Financial Officer | C/O JAVELIN PHARMACEUTICALS, INC., 125 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140 |
From GuruFocus
By Business Wire • 06-13-2024
By Business Wire • 03-28-2024
By Marketwired • 06-13-2024
By Business Wire • 05-29-2024
By Business Wire • 06-12-2024
By GuruFocus Research • 02-06-2024
By Business Wire • 05-08-2024
By GuruFocus Research • 02-06-2024
By GuruFocus Research • 02-06-2024
By Business Wire • 02-12-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.